Myeloid-derived Suppressor Cells in Sepsis
NCT03540797 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 125
Last updated 2018-05-31
Summary
This study is designed for septic patients, to isolate MDSCs and the correlation of prognosis of sepsis. The purpose of this study hopes to explore the phenomenon and possible mechanisms of MDSCs in patients with severe sepsis.
Conditions
Sponsors & Collaborators
-
Chung Fu-Tsai
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-07-01
- Primary Completion
- 2023-12-31
- Completion
- 2023-12-31
Countries
- Taiwan
Study Locations
More Related Trials
-
The Predictive Value of Hepatocyte Growth Factor and Soluble Receptor s-Met in Sepsis
NCT03340649 ·Status: UNKNOWN
-
Dendritic Cells-Derived Exosomes in Human Sepsis
NCT02957279 ·Status: UNKNOWN
-
Biomarkers in Exhaled Breath Condensates of Septic Patients to Predict Development of Multi-organ Dysfunction Syndrome
NCT01503684 ·Status: UNKNOWN
-
Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock
NCT05969275 ·Status: RECRUITING ·Phase: PHASE2
-
Effect of Immunophenotype on Prognosis of Sepsis
NCT05602584 ·Status: UNKNOWN
-
The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration
NCT06994312 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Effect of Mesenchymal Stromal Cells on Sepsis and Septic Shock
NCT05283317 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Identification and Clinical Efficacy Analysis of Biomarkers in Sepsis Patients
NCT05911711 ·Status: UNKNOWN
-
Co-inhibitory Molecules on Treg and miR-155-5p in Patients With Sepsis
NCT05126537 ·Status: UNKNOWN
-
PD-1/PD-L1 Pathway Study on Septic Patients
NCT01161745 ·Status: COMPLETED
-
The Application of SERS and Metabolomics in Sepsis
NCT02213237 ·Status: UNKNOWN
-
Application of Stimulated Immune Response Change to Predict Outcome of Patient With Severe Sepsis
NCT02887274 ·Status: UNKNOWN
-
Study on the Role of Gamma Delta T Cells in Sepsis Immunosuppression and Its Molecular Mechanism
NCT02361970 ·Status: COMPLETED
-
Cytokine Response in Septic Shock
NCT01770457 ·Status: UNKNOWN
-
Urine Interleukin-37 as a Biomarker of Mortality Risk in Patients With Sepsis
NCT05640037 ·Status: COMPLETED
-
Serial Body Composition Change for Risk Prediction and Nutritional Guide in Treating Patients With Sepsis
NCT04989569 ·Status: COMPLETED ·Phase: NA
-
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Dose Exploration Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Characteristics of STC314 Injection Administered Intravenously in Sepsis Patients
NCT06548854 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Mitochondrial Function of Immune Cells in Sepsis
NCT01600989 ·Status: COMPLETED
-
Monitoring Mitophagy In Myeloid Cells Upon Intensive Care
NCT05040503 ·Status: COMPLETED ·Phase: NA
-
Effect of Metformin Use on Mortality in Diabetic and Non Diabetic Patients With Sepsis and Septic Shock.
NCT05572060 ·Status: UNKNOWN ·Phase: NA
-
Investigate the Activity of Endotoxin in Severe Sepsis
NCT01957254 ·Status: TERMINATED
-
Reconstruction of Monocytic Immunocompetence by Granulocyte-macrophage-colony Stimulating Factor (GM-CSF) in Patients With Severe Sepsis and Septic Shock
NCT00252915 ·Status: COMPLETED ·Phase: PHASE2
-
The Role of Angiopoietin, Tie-2, and Vascular Endothelial Growth Factor (VEGF) in Sepsis-Induced Multiple Organ Dysfunction Syndrome (MODS)
NCT00908635 ·Status: UNKNOWN
-
Homocysteine in Patients With Sepsis
NCT04548414 ·Status: UNKNOWN
-
Cellular Immunotherapy for Septic Shock
NCT03369275 ·Status: UNKNOWN ·Phase: PHASE2